{"ORPHApacket":[{"ORPHApacketID":"276585","date":"2019-07-19 08:13:43","version":"1.2.11 \/ 4.1.6 [2018-04-12] (orientdb version)","copyright":"Orphanet (c) 2019","ORPHA":"276585","Name":[{"lang":"en","label":"Diazoxide-resistant hyperinsulinism"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_276585","DisorderType":[{"Name":[{"lang":"en","label":"Group of phenomes"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_377794"}],"SubClassOfList":[{"Disorder":[{"Name":[{"lang":"en","label":"Congenital isolated hyperinsulinism"}],"ORPHA":"657","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_657"}]}],"TextSection":[{"Name":[{"lang":"en","label":"Disease definition"}],"Contents":"Diazoxide-resistant hyperinsulism (DRH) is form of congenital isolated hyperinsulism (see this term) caused by an abnormal insulin production by b-cells in the pancreas that can be diffuse or focal and is characterized by an excessive\/ uncontrolled insulin secretion (inappropriate for the level of glycemia), recurrent episodes of profound hypoglycemia and resistance to medical management with diazoxide."}],"SynonymList":[{"count":"1","Synonym":[{"lang":"en","label":"Diazoxide-resistant hyperinsulinemic hypoglycemia"}]}]}]}